IntegraGen nabs rights to colorectal cancer biomarker; BioMarker Strategies names new CEO;

> France's IntegraGen has picked up the exclusive licensing rights for the oncology biomarker hsa-miR-31-3p, a microRNA whose expression has been shown to be a predictor of progression-free survival in patients with metastatic colorectal cancer treated with anti-EGFR therapy. Release

> BioMarker Strategies named Jerry Parrott as president, CEO and director. More

Sponsored By Metabolon

Five Translational Insights Key to a Successful First-in-Human (FIH) Study – Metabolite-Based Biomarker Discovery and Validation

Translational success rates from pre-clinical animal studies to human clinical trials remain frustratingly low. Learn how metabolomics helps you bridge between the theoretical & practical, between the function & actual activity of your drug molecule to get you closer to the phenotype, sooner.